Ibogaine Therapy: 3 Pros and 3 Cons

• By Karla Tafra
• May 5, 2021July 12, 2026
• Ibogaine Articles ibogaine side effects ibogaine therapy ibogaine treatment psychedelics psychedelics side effects
• With 1 comment

Last reviewed and updated: July 12, 2026.

Key Takeaways

In a world gripped by psychedelic exploration, today we focus specifically on Ibogane therapy’s pros and cons. If you’re considering Ibogaine therapy as a way to treat issues such as addiction, read on.

RELATED: Is Ibogaine Legal In The United States?

A Brief History of Ibogane Therapy

Used traditionally by the Bwiti tribe in West Central Africa, Ibogaine is a psychedelic found in the iboga tree. Ibogaine was first discovered by Western culture in the early 1900s by French explorers and became used in Europe as a stimulant.

Ibogaine’s power of detoxifying patients off of heroin was first discovered by Howard Lotsof. A heroin addict himself, Howard realized that ibogaine did not cause withdrawal symptoms. Based on these findings, he founded the Global Ibogaine Therapy Alliance, which is still alive and thriving. 

RELATED: These are the Best Ibogaine Treatment Centers Around the Globe

Challenges Faced by Ibogane Researchers

The use of ibogaine for personal and scientific purposes was banned in 1967. Classified as a Schedule Class I substance, Ibogane research all but dried up. Still, the Global Ibogaine Therapy Alliance’s initial results caused many interested parties to keep on exploring. Ibogaine therapy centres for treating addiction, for example, still exist.

The next step in Ibogaine research didn’t emerge until the early 1990s. The US National Institute on Drug Abuse (NIDA) began the development of Ibogaine through fully funded, pre-clinical animal trials. 

This led to FDA-approved Phase 1 Ibogaine safety trials on humans, performed at the University of Miami. The trial results confirmed that ibogaine decreases the self-administration of stimulants, opiates and alcohol. It also causes a significant reduction in withdrawal symptoms.

Ibogaine therapy has the potential to signal some great news for those addicted to opioids. However, due to the scarcity of performed studies and valuable large-scale results, downsides remain unknown.

Here are 3 pros and cons of ibogaine therapy.

RELATED: Looking For Addiction Treatment In Portugal? Here’s Why Iboga Or Ibogaine May Be An Option

The Pros of Ibogaine Therapy

1. Treats Addiction – Ibogaine interrupts addiction in a way that resets neurons. This reprograms us to pre-addicted states. Ibogaine acts as a reset button that eases relapsing.
2. Reduces Withdrawal Symptoms – Ibogaine can significantly reduce withdrawal symptoms and decrease relapses. Opioid withdrawal symptoms are painful and extremely difficult. Even if short lived, Ibogaine therapy can prove incredibly helpful in this respect.
3. Improves Mental States of Withdrawal – Ibogaine therapy has a profound effect on those battling with opioid withdrawal. Depression and anxiety, for example, aren’t rare consequences of this battle. Existing Ibogaine therapy studies have shown an overall healthier outlook overall. It also develops a stronger willpower to push through treatment.

The Cons of Ibogaine Therapy

1. Number of Studies – Ibogaine is classified as a Schedule Class I substance. As such, serious approvals, reasoning, and funding are necessary for research to even take place. As long as this number stays low, attempts to make it a widespread addiction treatment will be difficult. 
2. Number of Participants in Ibogaine Studies – In Ibogaine studies, the number of tested subjects is very low. First, those wanting to be a part of the study need to volunteer. Second, ibogaine’s classification has left many questioning how a hallucinogenic drug could help treat addiction. 
3. Consequences of Microdosing – Ibogaine therapy is still in its infancy. Microdosing should take place under direct supervision of a trained medical professional. Unfortunately, that isn’t always the case. Serious Ibogaine side effects like seizures, heart complications, ataxia, and even death may occur.

RELATED: Ego Death: Is This The Most Important Result From Psychedelic Therapy?

Ibogane Therapy: The Bottom Line

Ibogaine has a mortality rate of 1 in every 300 patients, The Multidisciplinary Association for Psychedelic Studies estimates. And since ibogaine therapy isn’t regulated, it’s hard to know how well staff has been trained and what their credentials are. 

Ibogaine treatment won’t be the next best way to tackle opioid addiction. While promising, potential negative consequences deter medical professionals from pursuing it. As all other psychedelic research gains traction, there’s only a matter of time before ibogaine will follow. As soon as more regulation and safety measures can be put in place, so will the trust in the treatment itself. 

Where Ibogaine Therapy Stands in 2026

The evidence behind ibogaine has grown stronger. In 2024, Stanford researchers led by Dr. Nolan Williams published a study in Nature Medicine. They treated roughly 30 Special Forces veterans who had traumatic brain injury and PTSD. Each veteran received ibogaine together with magnesium at a clinic in Mexico. The team reported large, durable reductions in PTSD, depression, and anxiety. Functional disability improved as well. The magnesium was not incidental. Doctors used it specifically to protect the heart during treatment.

The cardiac risk defines the main con. Ibogaine prolongs the QT interval, and that can trigger fatal heart arrhythmias. For that reason, safe treatment requires cardiac screening, continuous monitoring, and magnesium. Unsupervised retreats without medical staff are dangerous. Deaths have occurred with ibogaine. Almost all of them trace back to pre-existing heart problems or a lack of monitoring.

The legal picture is shifting slowly. Ibogaine remains a Schedule I substance under U.S. federal law. Legal, supervised treatment happens abroad, in countries such as Mexico and Costa Rica. In 2025, Texas approved a major public-private research initiative, widely reported at around $50 million, to fund ibogaine clinical trials toward FDA approval. That commitment is the largest any government has made to ibogaine research to date.

For anyone weighing the pros and cons in 2026, the trade-off is clear. The addiction-interruption and trauma results rank among the most striking in psychedelic medicine. The cardiac risk, however, is real and non-negotiable. Anyone considering ibogaine should treat cardiac screening and monitoring as mandatory, not optional. The April 2026 federal Executive Order on psychedelic medicine signals growing institutional attention to compounds like ibogaine.

Frequently Asked Questions

Is ibogaine legal in the United States?

No. Ibogaine is a Schedule I controlled substance federally. Legal, supervised ibogaine treatment is available in countries such as Mexico and Costa Rica. In 2025 Texas approved a major initiative to fund ibogaine clinical trials, which could eventually create a legal U.S. pathway if the FDA approves it.

What is ibogaine used to treat?

Ibogaine has been studied most for interrupting opioid and other substance addictions, and more recently for PTSD, depression, and traumatic brain injury. A 2024 Stanford study reported striking improvements in veterans with TBI and PTSD.

Why is ibogaine considered dangerous?

Ibogaine prolongs the heart’s QT interval and can cause life-threatening arrhythmias. Safe treatment requires cardiac screening, continuous heart monitoring, and magnesium. Most reported deaths involved pre-existing heart conditions or a lack of medical supervision.

How strong is the evidence for ibogaine?

The 2024 Stanford study in Nature Medicine is the most rigorous to date and reported large, durable benefits, but it was small and had no placebo group. Larger controlled trials, including those Texas is funding, are needed before ibogaine can be considered a proven treatment.